China Pharma Holdings (CPHI) EBIT (2010 - 2026)

China Pharma Holdings has reported EBIT for 17 years, with the latest figure at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 47.28% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$1.2 million (down 12.55% YoY), and the FY2025 full-year result was -$796890.0, up 32.7% from the prior year.
• EBIT for Q1 2026 stood at -$1.1 million, down from $1.2 million in the prior quarter.
• The five-year high for EBIT was $2.2 million in Q4 2024, with the low at -$1.4 million in Q2 2024.
• Historically, EBIT has averaged -$284803.9 across 5 years, with a median of -$688654.0 in 2022.
• Annual changes were most pronounced in 2022 — EBIT soared 316.78% — and 2024, when it plunged 204.95%.
• China Pharma Holdings' EBIT stood at $1.4 million in 2022, then slumped by 43.28% to $797625.0 in 2023, then soared by 176.91% to $2.2 million in 2024, then tumbled by 43.77% to $1.2 million in 2025, then slumped by 189.96% to -$1.1 million in 2026.
• The last three EBIT figures came in at -$1.1 million (Q1 2026), $1.2 million (Q4 2025), and -$628145.0 (Q3 2025), per Business Quant data.